Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: a case report

Highlights • Treatment with immunotherapy can induce vitiligo in patients with melanoma. • We describe the first case of vitiligo associated with nivolumab in lung cancer. • The patient developed vitiligo but had a good response to nivolumab treatment.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-07, Vol.109, p.42-44
Hauptverfasser:	Uenami, Takeshi, Hosono, Yuki, Ishijima, Mikako, Kanazu, Masaki, Akazawa, Yuki, Yano, Yukihiro, Mori, Masahide, Yamaguchi, Toshihiko, Yokota, Soichiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - diagnosis Adenocarcinoma - drug therapy Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Drug Resistance, Neoplasm Drug-Related Side Effects and Adverse Reactions - diagnosis Hematology, Oncology and Palliative Medicine Humans Immunotherapy - adverse effects Immunotherapy - methods Lung adenocarcinoma Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Male Neoplasm Staging Nivolumab Programmed Cell Death 1 Receptor - immunology Pulmonary/Respiratory Remission Induction Skin - pathology Vitiligo Vitiligo - diagnosis Vitiligo - etiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Treatment with immunotherapy can induce vitiligo in patients with melanoma. • We describe the first case of vitiligo associated with nivolumab in lung cancer. • The patient developed vitiligo but had a good response to nivolumab treatment.
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2017.04.019